相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effectiveness and Safety of Direct Oral Anticoagulants versus Vitamin K Antagonists for People Aged 75 Years and over with Atrial Fibrillation: A Systematic Review and Meta-Analyses of Observational Studies
Anneka Mitchell et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation A Systematic Review
Angela Lowenstern et al.
ANNALS OF INTERNAL MEDICINE (2018)
Direct oral anticoagulants versus warfarin: is new always better than the old?
John Burn et al.
OPEN HEART (2018)
Direct oral anticoagulants: analysis of worldwide use and popularity using Google Trends
Giuseppe Lippi et al.
ANNALS OF TRANSLATIONAL MEDICINE (2017)
Evaluation of bleeding in patients receiving direct oral anticoagulants
Erika L. Hellenbart et al.
VASCULAR HEALTH AND RISK MANAGEMENT (2017)
Safety of Direct Oral Anticoagulants: Insights from Postmarketing Studies
Todd C. Villines et al.
AMERICAN JOURNAL OF MEDICINE (2016)
Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience
John Eikelboom et al.
AMERICAN JOURNAL OF MEDICINE (2016)
The safety and persistence of non-vitamin-K-antagonist oral anticoagulants in atrial fibrillation patients treated in a well structured atrial fibrillation clinic
Faris Al-Khalili et al.
CURRENT MEDICAL RESEARCH AND OPINION (2016)
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Paulus Kirchhof et al.
EUROPEAN HEART JOURNAL (2016)
Characterizing Major Bleeding in Patients With Nonvalvular Atrial Fibrillation: A Pharmacovigilance Study of 27 467 Patients Taking Rivaroxaban
Sally Tamayo et al.
CLINICAL CARDIOLOGY (2015)
Novel Oral Anticoagulants in Patients With Renal Insufficiency: A Meta-analysis of Randomized Trials
Partha Sardar et al.
CANADIAN JOURNAL OF CARDIOLOGY (2014)
Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
Jonathan L. Halperin et al.
CIRCULATION (2014)
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Christian T. Ruff et al.
LANCET (2014)
New oral anticoagulant agents - general features and outcomes in subsets of patients
Sam Schulman
THROMBOSIS AND HAEMOSTASIS (2014)
What is the role of hemodialysis for dabigatran-associated major bleeding?
Benjamin Kim et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2014)
Overview of the coagulation system
Sanjeev Palta et al.
INDIAN JOURNAL OF ANAESTHESIA (2014)
What is the effect of rivaroxaban on routine coagulation tests?
Deborah M. Siegal et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2014)
Correlating prothrombin time with plasma rivaroxaban level
Ryan Rodgers et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
A Novel Prothrombin Time Assay for Assessing the Anticoagulant Activity of Oral Factor Xa Inhibitors
Yu Chen Barrett et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2013)
The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban-An Oral, Direct Factor Xa Inhibitor
Dagmar Kubitza et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
Robert P. Giugliano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
Manesh R. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Venous thrombosis in the elderly: incidence, risk factors and risk groups
M. J. Engbers et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Dabigatran versus Warfarin in Patients with Atrial Fibrillation.
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Hemostasis and aging
Massimo Franchini
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2006)
Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects
D Kubitza et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor
D Kubitza et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
分享论文
